The concluding learning point is the key. Extrapolate a study’s results beyond a study’s population at your peril. If you really want to know whether an intervention works in a different population, go out and test it properly.
Good question! There was a signal for an increase in colonic neoplasms with prasugrel in the TRITON-TIMI 38 trial (13 patients (0.2%) vs 4 patients (0.1%), p=0.03)
The concluding learning point is the key. Extrapolate a study’s results beyond a study’s population at your peril. If you really want to know whether an intervention works in a different population, go out and test it properly.
Why was new non-benign neoplasm a safety endpoint?
Good question! There was a signal for an increase in colonic neoplasms with prasugrel in the TRITON-TIMI 38 trial (13 patients (0.2%) vs 4 patients (0.1%), p=0.03)